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ABSTRACT
Objective: The aim of the present study was to determine whether curcumin (CM) can prevent drug sensitivity of breast cancer (BC) cells when E and 
β-E2 are administered together and whether the underlying mechanism involves modulation of drug efflux transporters.
Methods: MCF7 BC cells were treated with the vehicle only, E+β-E2, or E+β-E2+CM repeatedly for 8 weeks. Afterward, the cells were harvested, 
counted, and isolated for total RNA extraction. Total RNA was then processed into cDNA and further processed for the determination of mRNA 
expression patterns of drug efflux transporters (P-glycoprotein, BCRP, and MRP1).
Results: Decreased sensitivity of BC cells was shown by the increased cell viability of MCF7 cells after 8 weeks. This condition was accompanied with 
increased mRNA expression of P-glycoprotein, BCRP, and MRP1 in cells treated with E+β-E2, as compared with the vehicle only. CM, administered in 
combination with E+β-E2, resulted in decreased cell viability versus E and β-E2 and also decreased in mRNA expression of P-glycoprotein, BCRP, and 
MRP1.
Conclusion: CM partially reversed the sensitivity loss of BC cells to E in the presence of β-E2 by modulating drug efflux transporters.
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INTRODUCTION
Breast cancer (BC) is the most common type of cancer in women. 
Treatments for BC include surgery, radiation therapy, endocrine 
therapy, and chemotherapy. For endocrine therapy, tamoxifen (TMX) 
is the most common estrogen receptor (ER) modulator prescribed for 
ER-positive BC [1].
TMX is metabolized by CYP3A4 and CYP2D6 into several metabolites, 
which include 4-hydroxy-TMX, N-desmethyl-TMX, and 4-hydroxy-
N-desmethyl-TMX, which is also known as endoxifen (E) [2]. E is 
an active metabolite of TMX that has recently been developed as a 
new endocrine therapeutic agent for BC patients unresponsive to 
antiestrogen treatment [3]. E exerts its anticancer effects by degrading 
ER alpha, which leads to the inhibition of estrogen-induced BC cell 
proliferation [4]. However, BC cell resistance to endocrine treatment, 
including E, is likely to develop overtime [5-7].
Numerous mechanisms are responsible for the development of 
endocrine resistance, including downregulation of components in the 
ER signaling pathway, alterations to the cell cycle, crosstalk with growth 
factor signaling pathways, BC stem cells, and modulation of drug 
transporters [6,8]. A known mechanism of BC cell resistance to TMX is 
the overexpression of the drug efflux transporters P-glycoprotein, BCRP, 
MRP1, and MRP2 [9,10]. E is also known as a P-glycoprotein substrate 
in vitro and in vivo [11]. Thus, BC cell resistance to E might also be due 
to the overexpression of various drug efflux transporters.
To overcome the emergence of the resistance phenomenon, many groups 
have attempted to generate inhibitors of drug efflux transporters [12]. 
Curcumin (CM), a natural diphenolic compound from Curcuma longa, 
exerts antiproliferative effects and modulates the activities of drug efflux 
transporters [12,13]. Therefore, the aim of the present study was to 
determine whether CM can prevent the decreased sensitivity of BC cells 
to E, when administered together with estradiol (β-E2) and whether the 
underlying mechanism involves modulation of drug efflux transporters.
MATERIALS AND METHODS
Materials and reagents
CM was purchased from Plamed Green Science Limited (Xi’an, China), 
E was purchased from Tocris Bioscience (Ellisville, MO, USA), and â-E2 
was purchased from Sigma-Aldrich Pte. Ltd. (Singapore). Dimethyl 
sulfoxide (DMSO) was purchased from Vivantis Technologies Sdn Bhd 
(Malaysia). High-glucose Dulbecco’s modified Eagle’s medium (DMEM), 
heat-inactivated fetal bovine serum (FBS), penicillin/streptomycin, 
and fungizone were purchased from Biowest LLC (Riverside, MO, 
USA). The High Pure RNA Isolation Kit, Transcriptor First Strand cDNA 
Synthesis Kit, and FastStart DNA Master SYBR Green I were purchased 
from Roche Molecular Systems, Inc. (Pleasanton, CA, USA). Primers for 
P-glycoprotein, BCRP, MRP1, and â-actin were purchased from 1st BASE 
Pte Ltd. (Singapore).
Cell culture
MCF-7 BC cells were kindly provided by Makmal Terpadu Laboratory, 
Faculty of Medicine, Universitas Indonesia. The cells were maintained 
in DMEM high glucose supplemented with 10% FBS, 10 U/mL 
penicillin, 100 µg/mL streptomycin, and 2.5 µg/mL fungizone at 37°C 
in a humidified atmosphere of 5% CO2.
Drug preparation
E, β-E2, and CM were diluted in DMEM to the desired concentrations. 
A DMSO concentration of <0.001% was used as a negative control 
throughout this study.
Drug treatment
MCF7 cells were seeded into the wells of a 6-well plate at 10,000 cells 
per well and further treated with control (DMSO) or E 1 µM, E 1 
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µM+β-E2 1 nM, E 1 µM+β-E2 1 nM+CM 8.5 µM, or E 1 µM+β-E2 1 nM+CM 
17 µM 3 times weekly for 8 weeks. The cells were passaged every week 
following trypsinization and counting. Afterward, 10,000 cells were 
replated in complete medium for 72 h before the addition of drugs. Each 
treatment was conducted 3 times in duplicate.
Cell viability assay
Cell viability was determined using the trypan blue dye exclusion 
assay. The number of viable cells was counted using a hemocytometer. 
The results are expressed as the percentage relative to the control 
cells.
Quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR) analysis
Total cellular RNA was extracted from cell pellets using the high pure 
RNA isolation kit in accordance with the manufacturer’s protocol. RNA 
(1 µg in 20 µL) was converted to cDNA using the Transcriptor First 
Strand cDNA Synthesis kit. qRT-PCR was performed using the FastStart 
DNA Master SYBR Green I kit, according to the manufacturer’s protocol, 
with β-actin as the housekeeping gene, and qRT-PCR was performed 
with the following primers: β-actin (F: 5′-TTC GGC TTG CAA CAA CTA 
TG-3′; R: 5′-TCC AGA CAC ACC ACG GAT AA-3′), P-glycoprotein (F: 5′-TTA 
CAT TCA GGT TTC ATT TTG GTG-3′, R: 5′-TTC TGT CGC ATT ATA GCA 
TGA-3′), BCRP (F: 5′-TTC GGC TTG CAA CAA CTA TG-3′; R: 5′-TCC AGA 
CAC ACC ACG GAT AA-3′), and MRP1 (F: 5′-ATG TCA CGT GGC CTA CCA 
GC-3′; R: 5′-GAA GAC TGA ACT CCC TTC CG-3′).
The total reaction volume was 20 µL. Reactions were performed in a 
32-well plate using a LightCycler® Nano Instrument (F. Hoffmann-
La Roche Ltd., Basel, Switzerland) with the following cycling 
conditions: 95°C for 10 min, followed by 45 cycles at 95°C for 20 
s and annealing temperature of 55°C for 1 min for β-actin or 53°C 
for 20 s for P-glycoprotein, MRP1, and BCRP. The raw quantification 
cycle (Cq) values were analyzed by relative quantification using the 
Livak method to determine normalized expression ratios of target 
genes.
Data analysis
Data were analyzed by one-way analysis of variance followed by the 
Tukey method, with α=0.05, and are presented as the mean ± standard 
deviation. All statistical analyses were performed with GraphPad Prism 
6 software (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
E in the presence of β-E2 showed good control of cell viability in the 
1st week of drug treatment. Concomitant treatment with E and CM 
in the presence of β-E2 showed a synergistic effect, with additional 
suppression of cell viability (Fig. 1). However, after 8 weeks of treatment 
with E and β-E2, the efficacy of E was clearly lost, as BC cell viability 
had surpassed that of the control cells. Concomitant treatment with 
a low concentration of CM did not improve the sensitivity of BC cells 
to E, whereas larger concentrations showed good suppression of cell 
viability after 8 weeks of treatment (Fig. 1).
P-glycoprotein mRNA analysis showed that continuous treatment 
with E + β-E2 resulted in increased expression, whereas concomitant 
treatment with CM both at low and high concentrations reversed 
expression levels back to normal (Fig. 2).
BCRP mRNA expression was also increased after 8 weeks of treatment 
with E and β-E2. CM at both concentrations was shown to suppress 
BCRP mRNA expression but not potent enough to reverse expression 
back to control values (Fig. 3).
Continuous treatment with E in the presence of β-E2 was also shown 
to increase MRP1 mRNA expression. However, lower concentrations of 
CM failed to suppress the increased expression of MRP1, whereas CM at 
higher concentrations tended to suppress MRP1 mRNA expression, but 
the effect was not sufficiently potent (Fig. 4).
DISCUSSION
Endocrine therapy is the most effective treatment for patients with ER-
positive BC. However, treatment effectiveness is limited by high rates 
of de novo and acquired resistance during treatment [8]. E, an active 
metabolite of TMX, can also fail because of acquired resistance [6,7]. 
Hence, the aim of the present study was to determine the efficacy of CM 
administered for the prevention of decreased sensitivity of BC cells to E 
by coadministration with β-E2.
The efficacy of E on cell viability was lost after treatment for 8 weeks. 
E is a new drug under development for the treatment of advanced BC; 
thus, few studies have investigated the mechanism of E resistance.
Several studies have argued that epithelial-mesenchymal transition, 
which is characterized by increased vimentin expression, might play 
a significant role in the development of E resistance [7]. In addition, 
Squirewell et al. [14] argued that E may affect the ability of human 
Fig. 1: Cell viability after MCF7 treatment with dimethyl sulfoxide 
or E+β-E2 or E+β-E2+CM 8.5 µM or E+β-E2+CM 17 µM for 8 weeks. 
End+β-E2 = E 1 µM+β-E2 1 nM, EB+CM8.5 = E 1 µM+β-E2 1 nM+CM 
8.5 µM, EB+CM17 = E 1 µM+β-E2 1 nM+CM 17 µM
Fig. 2: P-glycoprotein mRNA expression after MCF7 treatment 
with dimethyl sulfoxide or E+β-E2 or E+β-E2+CM 8.5 µM or E+β-
E2+CM 17 µM for 8 weeks. *Significantly different from DMSO at 
p<0.05; ##significantly different from E+β-E2 at p<0.001. End + 
β-E2 = E 1 µM+β-E2 1 nM, EB+CM 8.5 = E 1 µM+β-E2 1 nM+CM 
8.5 µM, EB+CM17 = E 1 µM+β-E2 1 nM+CM 17 µM
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estrogen sulfotransferase 1E1 and human phenol sulfotransferase 1A1 
isoform 1 to catalyze the sulfation of β-E2, which plays important roles 
in the termination of estrogen signaling through the loss of ER activity.
Drug efflux transporters are involved in the decreased sensitivity 
of BC cells to TMX [9,10]. In the present study, the sensitivity of 
BC cells to E was diminished, which was followed by increased 
activities of the drug efflux transporters P-glycoprotein, BCRP, and 
MRP1. According to Teft et al. [15], E is a substrate of P-glycoprotein 
(multidrug resistance 1). However, it remains unclear as to whether E 
induces or inhibits P-glycoprotein expression.
CM, a polyphenol derived from C. longa, has a wide range of beneficial 
properties as a chemotherapeutic agent and modulator of ABC efflux 
transporters [12,13]. A recent study also showed that CM administered 
together with TMX increased the anticancer activity, as compared 
with TMX alone. This effect may occur through the suppression of 
P-glycoprotein (MDR1) expression [16-18]. Squirewell et al. [14] 
proposed a mechanism of the interactions of polyphenols, including CM, 
with ABC transporters and showed that polyphenols counteracted tumor 
cell chemoresistance by interacting with the ATP-binding domains of 
P-glycoprotein and inhibits its ATPase activity site and steroid interacting 
regions of the protein cytosolic domains [13]. However, for a flavonoid 
to interact with MRP1, it also needs transport stimulation of reduced 
glutathione [1,19]. This phenomenon might explain the different patterns 
of CM effects in regard to P-glycoprotein, BCRP, and MRP1.
Low-concentration CM failed to reverse the decreased sensitivity of E, 
even when mRNA expression levels of P-glycoprotein and BCRP were 
significantly decreased. This finding suggests that MRP1 expression 
might be the most consistent match with cell viability. Hence, MRP1 
might be the dominant transporter in the development of decreased 
sensitivity of BC cells to E.
CONCLUSION
CM partially reversed the loss of sensitivity of BC cells to E in the 
presence of β-E2 by modulation of the drug efflux transporters 
P-glycoprotein, BCRP, and MRP1. CM should be further investigated 
as a drug candidate for the prevention of E resistance in BC. However, 
further studies are needed to elucidate the underlying mechanisms.
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